GIP and GLP-1 receptor co-agonist
Tirzepatide 15 mg subcutaneous once weekly
TIRZ_SC_15MG_QW
Related
- All doses pooled: Tirzepatide injection
- Tirzepatide 1 mg subcutaneous once weekly
- Tirzepatide 5 mg subcutaneous once weekly
- Tirzepatide 10 mg subcutaneous once weekly
- Tirzepatide maximum tolerated dose injection once weekly
- Tirzepatide subcutaneous once weekly, maximum tolerated dose: 10 or 15 mg
- Tirzepatide 12 mg injection once weekly
Effects across outcomes
Bayesian random effects estimate against the comparator of each analysis (usually placebo), posterior median and 95% credible interval. Green: clearly better; red: clearly worse.
| Condition | Outcome | Window | Versus | Effect (95% CrI) | SUCRA |
|---|---|---|---|---|---|
| Type 2 diabetes (adults) | HbA1c change | weeks 20 to 36 (target week 26) | Placebo | MD -1.86 (-2.20 to -1.52) | 0.98 |
| Type 2 diabetes (adults) | HbA1c change | weeks 36 to 64 (target week 52) | Placebo | MD -0.53 (-1.05 to 0.02) | 0.78 |
| Type 2 diabetes (adults) | HbA1c change | weeks 36 to 64 (target week 52) | Placebo | MD -2.26 (-2.74 to -1.65) | 0.97 |
| Type 2 diabetes (adults) | HbA1c change | weeks 36 to 64 (target week 52) | Placebo | MD -1.68 (-2.08 to -1.17) | 0.95 |
| Type 2 diabetes (adults) | HbA1c change | weeks 36 to 64 (target week 52) | Placebo | MD -2.03 (-2.81 to -0.75) | 0.88 |
| Type 2 diabetes (adults) | Body weight change in kilograms (diabetes) | weeks 20 to 36 (target week 26) | Placebo | MD -10.32 (-12.51 to -8.10) | 1.00 |
| Type 2 diabetes (adults) | Body weight change in kilograms (diabetes) | weeks 36 to 64 (target week 52) | Placebo | MD -11.38 (-14.21 to -7.82) | 0.99 |
| Type 2 diabetes (adults) | Body weight change in kilograms (diabetes) | weeks 20 to 36 (target week 26) | Placebo | MD -9.59 (-12.14 to -7.00) | 0.96 |
| Type 2 diabetes (adults) | Body weight change in kilograms (diabetes) | weeks 36 to 64 (target week 52) | Placebo | MD -7.14 (-11.33 to -2.22) | 0.89 |
| Type 2 diabetes (adults) | Body weight change in kilograms (diabetes) | weeks 36 to 64 (target week 52) | Placebo | MD -12.39 (-14.56 to -9.46) | 1.00 |
| Type 2 diabetes (adults) | Body weight change in kilograms (diabetes) | weeks 36 to 64 (target week 52) | Placebo | MD -8.54 (-12.63 to -2.62) | 0.93 |
| Type 2 diabetes (adults) | HbA1c below 7 percent | weeks 20 to 36 (target week 26) | Placebo | OR 20.28 (4.69 to 63.94) | 0.87 |
| Type 2 diabetes (adults) | HbA1c below 7 percent | weeks 36 to 64 (target week 52) | Tirzepatide 10 mg subcutaneous once weekly | OR 1.17 (0.51 to 2.60) | 0.88 |
| Type 2 diabetes (adults) | HbA1c below 7 percent | weeks 36 to 64 (target week 52) | Placebo | OR 20.38 (1.23 to 74.89) | 0.71 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 0.05 (0.00 to 0.77) | 0.81 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 3.26 (1.39 to 8.10) | 0.37 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 0.73 (0.26 to 1.97) | 0.58 |
| Type 2 diabetes (adults) | Systolic blood pressure change | weeks 20 to 36 (target week 26) | Placebo | MD -2.22 (-7.06 to 2.49) | 0.51 |
| Type 2 diabetes (adults) | Systolic blood pressure change | weeks 36 to 64 (target week 52) | Placebo | MD 0.02 (-5.06 to 5.08) | 0.70 |
| Type 2 diabetes (adults) | Weight loss of 5 percent or more | weeks 20 to 40 (target week 26) | Placebo | OR 34.08 (8.12 to 147) | 0.92 |
| Type 2 diabetes (adults) | Weight loss of 10 percent or more | weeks 20 to 40 (target week 26) | Placebo | OR 18.13 (3.88 to 88.70) | 0.88 |
| Type 2 diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 0.70 (0.54 to 0.92) | 0.69 |
| Type 2 diabetes (adults) | Discontinuation due to adverse events | longest follow-up | Placebo | HR 2.07 (1.35 to 3.33) | 0.40 |
| Type 2 diabetes (adults) | Nausea | longest follow-up | Placebo | HR 4.17 (3.15 to 5.53) | 0.31 |
| Type 2 diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 3.67 (2.50 to 5.41) | 0.39 |
| Type 2 diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 3.07 (2.37 to 3.98) | 0.21 |
| Type 2 diabetes (adults) | Constipation | longest follow-up | Placebo | HR 3.57 (2.31 to 5.64) | 0.19 |
| Type 2 diabetes (adults) | Discontinuation due to gastrointestinal adverse events | longest follow-up | Placebo | HR 1.47 (0.08 to 31.64) | 0.52 |
| Type 2 diabetes (adults) | Acute pancreatitis | longest follow-up | Placebo | HR 0.55 (0.04 to 6.07) | 0.57 |
| Type 2 diabetes (adults) | Diabetic retinopathy complications | longest follow-up | Placebo | HR 0.69 (0.01 to 46.52) | 0.56 |
| Type 2 diabetes (adults) | Pancreatic cancer | longest follow-up | Placebo | HR 0.77 (0.05 to 12.14) | 0.51 |
| Overweight or obesity without diabetes (adults) | Percent body weight change | weeks 40 to 104 (target week 68) | Placebo | MD -19.48 (-24.79 to -9.44) | 0.77 |
| Overweight or obesity without diabetes (adults) | Percent body weight change | weeks 40 to 104 (target week 68) | Placebo | MD -7.89 (-12.80 to -3.02) | 0.51 |
| Overweight or obesity without diabetes (adults) | Weight loss of 5 percent or more | weeks 40 to 104 (target week 68) | Placebo | OR 23.72 (5.73 to 90.52) | 0.65 |
| Overweight or obesity without diabetes (adults) | Weight loss of 10 percent or more | weeks 40 to 104 (target week 68) | Placebo | OR 5.36 (1.36 to 20.11) | 0.46 |
| Overweight or obesity without diabetes (adults) | Weight loss of 15 percent or more | weeks 40 to 104 (target week 68) | Placebo | OR 7.91 (1.86 to 37.51) | 0.57 |
| Overweight or obesity without diabetes (adults) | Weight loss of 20 percent or more | weeks 40 to 104 (target week 68) | Placebo | OR 13.77 (2.27 to 151) | 0.75 |
| Overweight or obesity without diabetes (adults) | SF-36 physical component summary change | weeks 20 to 130 (target week 52) | Placebo | MD 2.51 (-5.40 to 10.36) | 0.61 |
| Overweight or obesity without diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 1.04 (0.60 to 1.98) | 0.54 |
| Overweight or obesity without diabetes (adults) | Nausea | longest follow-up | Placebo | HR 4.11 (2.96 to 5.74) | 0.42 |
| Overweight or obesity without diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 6.59 (3.77 to 11.76) | 0.32 |
| Overweight or obesity without diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 3.66 (2.37 to 5.82) | 0.21 |
| Overweight or obesity without diabetes (adults) | Constipation | longest follow-up | Placebo | HR 2.43 (1.33 to 4.54) | 0.43 |
| Metabolic dysfunction associated steatotic liver disease or steatohepatitis | Serious adverse events | longest follow-up | Placebo | HR 0.08 (0.00 to 1.12) | 0.97 |
| Metabolic dysfunction associated steatotic liver disease or steatohepatitis | Discontinuation due to adverse events | longest follow-up | Placebo | HR 2.26 (0.40 to 14.64) | 0.36 |
| Metabolic dysfunction associated steatotic liver disease or steatohepatitis | Nausea | longest follow-up | Placebo | HR 3.80 (1.15 to 11.80) | 0.37 |
| Metabolic dysfunction associated steatotic liver disease or steatohepatitis | Vomiting | longest follow-up | Placebo | HR 4.78 (0.78 to 33.08) | 0.46 |
| Metabolic dysfunction associated steatotic liver disease or steatohepatitis | Diarrhea | longest follow-up | Placebo | HR 1.18 (0.38 to 3.52) | 0.71 |
| Metabolic dysfunction associated steatotic liver disease or steatohepatitis | Constipation | longest follow-up | Placebo | HR 1.99 (0.43 to 8.66) | 0.50 |
| Metabolic dysfunction associated steatotic liver disease or steatohepatitis | Discontinuation due to gastrointestinal adverse events | longest follow-up | Placebo | HR 1.90 (0.20 to 17.91) | 0.51 |
Trials
- SURPASS-SWITCHA Phase 4, Randomized, Open-Label, Active-Controlled Study to Investigate the Efficacy and Safety of Switching From Weekly Dulaglutide to Weekly Tirzepatide in Adults With Type 2 Diabetes2022 · 282 randomized · 40 weeks
- SURMOUNT-CNEfficacy and Safety of Tirzepatide Once Weekly in Chinese Participants Without Type 2 Diabetes Who Have Obesity or Are Overweight With Weight-Related Comorbidities: A Randomized, Double-Blind, Placebo-Controlled Trial (SURMOUNT-CN)2021 · 210 randomized · 52 weeks
- NCT04081337A Randomized, Placebo-Controlled, Parallel-Arm Study to Investigate the Effect of Once-Weekly Tirzepatide on Energy Expenditure and Food Intake in Obese Subjects2020 · 55 randomized · 18 weeks
- SURPASS-6A Randomized, Phase 3, Open-label Trial Comparing the Effect of the Addition of Tirzepatide Once Weekly Versus Insulin Lispro (U100) Three Times Daily in Participants With Type 2 Diabetes Inadequately Controlled on Insulin Glargine (U100) With or Without Metformin (SURPASS-6)2020 · 1,428 randomized · 52 weeks
- NCT04235959A Multiple Dose Titration Study in Chinese Patients With Type 2 Diabetes Mellitus to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of Tirzepatide2020 · 24 randomized · 24 weeks
- SURMOUNT-1Efficacy and Safety of Tirzepatide Once Weekly in Participants Without Type 2 Diabetes Who Have Obesity or Are Overweight With Weight- Related Comorbidities: A Randomized, Double-Blind, Placebo-Controlled Trial (SURMOUNT-1)2019 · 2,539 randomized · 72 weeks
- SYNERGY-NASHA Randomized, Double-Blind, Placebo-Controlled Phase 2 Study Comparing the Efficacy and Safety of Tirzepatide Versus Placebo in Patients With Nonalcoholic Steatohepatitis (NASH)2019 · 190 randomized · 52 weeks
- SURPASS-1A Randomized, Double-blind, Placebo-Controlled Trial Comparing the Efficacy and Safety of Three Tirzepatide Doses Versus Placebo in Patients With Type 2 Diabetes, Inadequately Controlled With Diet and Exercise Alone2019 · 478 randomized · 40 weeks
- NCT03951753The Effect of Tirzepatide on α and β Cell Function and Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus2019 · 117 randomized · 28 weeks
- NCT04093752A Randomized, Phase 3, Open-label Trial Comparing the Effect of Tirzepatide Once Weekly Versus Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes on Metformin With or Without a Sulfonylurea2019 · 917 randomized · 40 weeks
- NCT03861039A Phase 3, Long-Term Safety Study of Tirzepatide in Combination With Monotherapy of Oral Antihyperglycemic Medications in Patients With Type 2 Diabetes Mellitus (SURPASS J-combo)2019 · 443 randomized · 52 weeks
- SURPASS-3A Randomized, Phase 3, Open-Label Trial Comparing the Effect of LY3298176 Versus Titrated Insulin Degludec on Glycemic Control in Patients With Type 2 Diabetes2019 · 1,444 randomized · 52 weeks
- SURPASS-5Randomized, Phase 3, Double-blind Trial Comparing the Effect of the Addition of Tirzepatide Versus Placebo in Patients With Type 2 Diabetes Inadequately Controlled on Insulin Glargine With or Without Metformin2019 · 475 randomized · 40 weeks
- SURPASS-4Efficacy and Safety of LY3298176 Once Weekly Versus Insulin Glargine in Patients With Type 2 Diabetes and Increased Cardiovascular Risk (SURPASS-4)2018 · 2,002 randomized · 104 weeks
- NCT03131687A Phase 2 Study of Once-Weekly LY3298176 Compared With Placebo and Dulaglutide in Patients With Type 2 Diabetes Mellitus2017 · 318 randomized · 26 weeks
- NCT03322631A Multiple-Ascending Dose Study in Japanese Patients With Type 2 Diabetes Mellitus to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY32981762017 · 48 randomized · 8 weeks